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ABSTRACT

Objective
To assess the efficacy of stem cells in the improvement of functional capacity and quality of life
in the setting of nonischemic dilated cardiomyopathy.

Design
Systematic literature review

Methods
A literature search of PubMed was conducted utilizing the following search terms: “stem,” “cell,”
“nonischemic,” and “cardiomyopathy.” The following limits were used: “2015-2018,” nonischemic
cardiomyopathy, results of LVEF and 6MWT, randomized controlled trials, pilot studies, and
sample size >22.

Results
Butler et al. found that within the itMSC group, 6MWD increased by an average of 27.40 m
(95% CI 0.28–54.52; P=0.05), but it decreased by an average of 10.83 m (95% CI −38.66 to
17.00, P=0.45) among control patients. The authors used exploratory analyses to examine
changes from baseline after initial randomization and found significant increases in LVEF in the
itMSC group (estimated mean difference was +2.31; P=0.02) with no significant changes in
control group (+1.62; P=0.13.). Vrtovec et al. revealed improvement in LVEF and 6MWT in both
single and repetitive dose groups (group A and group B), when comparing each group
separately from baseline to 6 months (LVEF: +6.9±3.3% in group A, P=0.001 and +7.1±3.5% in
group B, P=0.001; 6MWT: +87±21 m, P=0.03 and +92±25 m, P=0.02). Hare et al. found that at
12 months post-treatment, LVEF increased in the allo-hMSC group by 8.0% (CI: 2.8% to 13.2%,
p = 0.004) compared to baseline which was found to be statistically significant, but the LVEF
increase of 5.4% in the auto-hMSC group was not statistically significant (CI: -1.4% to 12.1%; p
= 0.116). At 12 months post-treatment, the 6MWT distance significantly increased in the allohMSC treatment group by 37.0 meters (CI: 2.0m to 72.0m, p = 0.04) compared to baseline. At
12 months post-treatment, the auto-hMSC treatment group 6MWT distance increased 7.3
meters compared to baseline and was not statistically significant (CI: -47.8m to 33.3m, p =
0.71).
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Conclusion
Stem cell therapy is shown to be safe, well-tolerated, and effective in improving functional
capacity, quality of life, and short-term event survival in patients with nonischemic
cardiomyopathy and, thus, is a promising alternative therapeutic option for patients with
nonischemic cardiomyopathy and should be further explored in future studies.

Abbreviations and Acronyms
AMI - Acute myocardial infarction
CHF - Chronic heart failure
G-CSF - Granulocyte colony-stimulating factor
HFrEF - Heart failure with reduced ejection fraction
hMSC - Human mesenchymal stem cells
ICD - Implantable cardioverter defibrillator
LVEF - Left ventricular ejection fraction
LVAD - Left ventricular assist device
MSC - Mesenchymal stem cells
NIDCM - Nonischemic dilated cardiomyopathy
NYHA - New York Heart Association
PAD - Peripheral artery disease
6MWD- 6-minute walk distance
6MWT - 6-minute walk test
TE-SAE - Treatment-emergent serious adverse events
TESI - Transendocardial stem cell injection
VO2 - Peak oxygen uptake
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INTRODUCTION
Nonischemic dilated cardiomyopathy (NIDCM), often referred to as heart failure with
reduced ejection fraction (HFrEF), is a disorder characterized by progressive degeneration and
structural change of cardiac tissue leading to impaired contractile function of the heart. Since
the only curative therapy for NIDCM at this time is heart transplantation, the primary goals of
treatment are to improve cardiac function, reduce the symptoms of heart failure, and delay the
need for heart transplantation for as long as possible.1 The burden of this disease is significant
as NIDCM is currently the most common cause of heart failure leading to heart transplantation,
accounting for 49.8% of all heart transplantations performed between January 2009 and June
2016.2 Over the past decade, the number of donor hearts available per year has remained
relatively stable, but the number of patients in advanced heart failure in need of transplantation
has risen significantly.3 It is currently estimated that dilated cardiomyopathy is responsible for
10,000 deaths and 46,000 hospitalizations each year in the USA.4 There are up to 50,000
candidates for heart transplantation each year worldwide, but only 5,000 cardiac transplants are
performed.5 Of those 10% who are lucky enough to receive a curative transplantation, 85% are
expected to survive the first year post-transplant and mean survival time for all heart transplant
recipients is estimated to be 11 years.6 The limited supply of donor hearts and the high pre- and
post-heart transplant mortality rates is evidence of a great need for additional heart failure
therapeutic and curative options.
Stem cell-based therapies seem to be a promising new treatment option for NIDCM
based on the results of several early phase clinical trials. Stem cells are a population of
immature, undifferentiated cells, which have the potential to develop into a number of different
specialized cell types. In the setting of NIDCM, it is hypothesized that stem cells have the
potential to 1) aid in cardiac myocyte regeneration, 2) secrete factors that reduce the rate of
apoptosis of endogenous cardiac myocytes, 3) promote angiogenesis, 4) activate endogenous
cardiac stem cells to promote regeneration of new healthy tissue, and 5) induce the release of
large amounts of anti-inflammatory factors which possibly have a significant role in myocyte
repair.7 The goal of stem cell therapy in the treatment of NIDCM is to regain normal function of a
damaged heart without the need for total heart transplantation.
End point measurements of cardiac improvement after stem cell therapy evaluated in
this paper include the 6-minute walk test distance (6MWT) and left ventricular ejection fraction
(LVEF). The 6MWT and LVEF are indicators of functional capacity in patients with heart failure.
This review will focus on recent evidence that stem cell therapy causes short term improvement
in the functional capacity of patients with nonischemic dilated cardiomyopathy.
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METHODS
An initial literature search of PubMed was conducted in September 2018 using the
following search terms: “stem,” “cell,” “nonischemic,” and “cardiomyopathy.” The initial search
yielded 83 results, 47 of which were excluded when the results were filtered by year: “20152018.” The remaining 36 full-text articles were assessed for eligibility. Review articles, case
reports, and animal trials were excluded. In addition, articles focusing on other disorders,
without 6MWT as an outcome, and with sample size <22 were excluded. The three articles that
remained
assessed

were
using

individually
critical

appraisal sheets and included
in this analysis. A level of
evidence

was assigned

to

each study based on John
Hopkins NURSING Evidence
Level and Quality Guide.8 A
summary of study criteria is
shown in Table 1. The PRISMA flow chart, seen below in Figure 1, summarizes the article
selection process.
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RESULTS
Study #1
Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy. Safety and
Efficacy Results of a Phase II-A Randomized Trial. Butler et al.9

Study Objective
“To assess the safety and preliminary efficacy of intravenously administered ischemia-tolerant
MSCs (itMSCs) in patients with nonischemic cardiomyopathy.”

9
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Study Design
This was a crossover randomized phase II-a trial involving 22 patients with nonischemic
cardiomyopathy with LVEF less than or equal to 40%, from across 4 sites in the United States,
between June 2014 and April 2016. Table 2 outlines patient inclusion and exclusion criteria.
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Thirty-four patients were screened, 23 were randomized, and 22 were involved in the study.
Eligible patients were blinded to treatment allocation and randomized 1:1 to either the control
group, “placebo-itMSC,” (n=12) or the intervention group, “itMSC” (n=10). Of note, the control
group data was defined as the data from the group which received the placebo treatment at time
t=0 days, "placebo-itMSC." The intervention group data was defined as the data from the group
which received the intervention treatment at time t=0 days, "itMSC," as well as the data from
"placebo-itMSC" from t=90 days to t=180 days. Both groups were evaluated from baseline at
t=0 days through t=90 days before crossover. At t=90 days, the "placebo-itMSC" group received
interventional treatment and the "itMSC" group received placebo treatment. The “itMSC” group
received placebo after the crossover from t=90 days through t=180 days, but was not included
in the data analysis of the control
group. The intervention treatment
was an intravenous (IV) infusion of
ischemia-tolerant

allogenic

mesenchymal stem cells (MSCs)
dosed

at

1.5

million

cells/kg

extracted from the bone marrow of a
healthy volunteer and suspended in
Lactated Ringer’s solution at a
concentration of 1x106 cells/mL. The
placebo was an IV infusion of
Lactated Ringer’s solution at 1
mL/kg. At t=90 days post-initial treatment, each group crossed over; the "placebo-itMSC" group
received intervention and the “itMSC” group received placebo, resulting in each patient
receiving a total of 2 infusions during the study. The study timeline and flow of patients through
the trial can be seen in Figure 2. 9
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Prior to treatment, demographic data, New York Heart Association (NYHA) class, vital
signs, laboratory data (AST/ALT, BNP, Troponin, Sodium, Creatinine, Total Bilirubin, and
Albumin), medical history, medications, and cardiac magnetic resonance imaging were collected
as baseline data. Mean age of study participants was 47.3 years, over two-thirds were
Caucasian, all but one patient had NYHA class II symptoms, and rate of comorbidities was low.
Secondary efficacy endpoints included LVEF and 6MWT, among others. LVEF was measured
at baseline, t=90 days, and t=180 days and 6MWT was measured at t=30 days and t=90 days
after initial and second transfusion. The flow of treatment can be seen in Figure 2 above. At
each time point, vital signs, 12-lead electrocardiograms, and laboratory tests were collected.
Twenty-four-hour Holter monitoring was also done at each time point up to t=270 days.
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Statistical analyses used a 2-sided 0.05 significance level. Continuous secondary efficacy
endpoints were analyzed using linear regression and 95% confidence intervals.

Study Results
At baseline, average LVEF was 31.6% ± 9.8%. At t=90 days, there was no significant
difference between “placebo-itMSC” or “itMSC” groups as the estimated difference in LVEF was
0.01% (95% CI -1.50-1.52; P=0.99). However, increases in LVEF in the itMSC group were
shown “in ad hoc exploratory analyses
that examined changes from baseline
after initial randomization (ie, first 90
days, pre crossover).” 9 The estimated
mean difference was +2.31 (P=0.02).
During this same time period, changes
in those patients who were receiving
placebo were not significant with a
LVEF estimated mean difference of
+1.62 (P=0.13).
“Treatment
resulted

in

with

statistically

itMSCs
significant

improvements in health status and
functional

capacity

end

points.”
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Compared to control, the change in
six-minute walk distance (6MWD) from
baseline to t=90 days after itMSC
therapy was “significantly greater by 36.47 m (95% CI 5.98–66.97; P=0.02) or 15.9% [(See
Figure 3)]. Specifically, within the “itMSC” group, 6MWD increased by an average of 27.40 m
(95% CI 0.28–54.52; P=0.05), but it decreased by an average of 10.83 m (95% CI −38.66 to
17.00, P=0.45) among control patients.” 9
In summary, these results support clinical efficacy of IV stem cell infusion of ischemiatolerant allogeneic MSCs in the setting of nonischemic dilated cardiomyopathy since a
statistically significant improvement from baseline was seen in the “itMSC” group in 6MWD and
in ad hoc exploratory analyses of LVEF, indicating a significant improvement of health status
and functional capacity in these patients as a result of this experimental therapy. If results of this
clinical trial are replicated in a larger randomized control trial, IV infusion of MSCs could be
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considered as a less invasive therapeutic option to improve functional capacity as well as shortterm event-free survival in patients with NIDCM.

Study Critique
Strengths of this study include the stringent inclusion and exclusion criteria as well as
the rigorous definition of nonischemic cardiomyopathy defined using multiple clinical and
objective parameters. Additionally, the use of multiple secondary efficacy endpoints helps to
decrease the likelihood of chance findings when the results correspond. This study was also
performed at 4 different sites in the US, limiting the chance of geographical elements.
This study is hampered by a small study size, though early phase studies primarily
focusing on safety often have small sample sizes. The use of exploratory ad hoc analyses also
provides an interesting challenge as significant results can be found, but still need prospective
validation. The fact that this study was a crossover study can be both a strength and a
hindrance. Crossover studies are helpful in that each participant acts as their own control,
limiting between-subject variability. However, crossover studies are also a weakness as the
researchers of this study “cannot definitively determine if any adverse event occurring>90 days
after itMSC infusion within the itMSC–placebo group represents placebo effect, delayed
consequence of cell therapy, or random chance.” An additional potential weakness in this study
is that only MSCs grown under hypoxic conditions were used, due to previous studies reporting
higher efficacy.10 The researchers did not test MSCs grown under normoxic conditions and,
therefore, cannot conclude whether the ischemia-tolerant MSCs played a different role than that
of normoxic MSCs.

Level of Evidence: 1B

Study #2
Effects of Repetitive Transendocardial CD34+ Cell Transplantation in Patients With
Nonischemic Dilated Cardiomyopathy. Vrtovec et al. 11
Study Objective
To investigate if repetitive administration of CD34+ cells is more effective than single
administration in patients with nonischemic dilated cardiomyopathy.
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Study Design
This was a prospective randomized study involving 60 patients with nonischemic
cardiomyopathy with LVEF less than or equal to 40%, “conducted at the Advanced Heart Failure
and Transplantation Center at University Medical Center Ljubljana between January 2014 and
September 2017 in collaboration with the Stanford Cardiovascular Institute.”

11

Table 3 outlines

patient inclusion and exclusion criteria. Of the 89 patients screened, 66 patients were enrolled,
and 6 were excluded due to inadequate response to granulocyte colony-stimulating factor (GCSF) stimulation, as the patient's own stem cells were used for the transplantation. The
remaining 60 patients were randomly allocated in 1:1 ratio to receive either repetitive (group A)
or single-dose (group B) CD34+ cell therapy. “During 1-year follow-up, there was 1 heart
transplantation in group A versus 1 death and 1 heart transplantation in group B. Of the 6
excluded patients, 1 patient died, and 1 underwent heart transplantation.”
and flow of patients through the trial can be seen in Figure 4.
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The study timeline
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At

baseline,

demographic

parameters,

LVEF,

exercise

capacity,

medications,

comorbidities, and renal and liver function tests did not differ between groups. Mean age was
55±10. Both groups received daily subcutaneous injections of G-CSF (10 μg/kg) for 5 days.
CD34+ cells were collected via apheresis with Miltenyi cell separator “and the magnetic cell
separator Isolex 300i was used for the immunomagnetic positive selection of the CD34+ cells.”11
A standardized dose of 80 million CD34+ cells was used for transendocardial injection, guided
by electronic mapping. “In group A, G-CSF stimulation, apheresis, electroanatomical mapping,
and cell injections were repeated at 6 months.” Clinical evaluation, echocardiography, and
6MWT were performed at baseline, 6 months, and 12 months. The primary end point of this
study was the change in LVEF over 12 months between the two groups. The 6MWT distance
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was a secondary end point, among others. “Favorable clinical response to cell therapy was
defined as the presence of increase in LVEF of at least 5% at 6 months after stem cell
transplantation.” 11
A blinded third party echocardiographer was recruited to analyze echocardiography data
at the conclusion of the study and all of the data was averaged over 5 cycles. LVEF was
estimated using the Simpson biplane method. In all patients, 6MWT was performed by a blinded
observer. Patients who died or underwent heart transplantation were excluded from statistical
analyses.

Study Results
At 1 year, there was no significant change in LVEF from 32.2±9.3% to 41.2±6.5% in
group A and from 30.0±7.0% to 37.9±5.3% in group B, resulting in P=0.40. Additionally, there
was no significant change in 6MWT between both groups at 1 year (from 320±92 to 434±71 m
in group A and from 341±87 to 445±96 m in group B, P=0.65). However, both groups showed
improvement in LVEF and 6MWT, when comparing each group separately, from baseline to 6
months (LVEF: +6.9±3.3% in group A, P=0.001 and +7.1±3.5% in group B, P=0.001; 6MWT:
+87±21 m, P=0.03 and +92±25 m, P=0.02). In contrast, there were no significant changes
between 6 months and 1 year in LVEF or 6MWT (LVEF: +2.1±2.3% in group A, P=0.19 and
+0.8±3.1% in group B, P=0.5; 6MWT: +27±11 m, P=0.2 and +12±18 m, P=0.42). These results
are summarized below in Figure 5. 11
In

summary,

these

results

do

not

support

clinical

superiority

of

repetitive

transendocardial CD34+ cell transplantation over single dose transplantation at this time. These
results do show statistically
significant improvement in
both LVEF and the 6MWT in
each separate group from
baseline

to

6

however,

there

months;
was

no

significant improvement in
LVEF or the 6MWT from 6
months

to

1

year,

suggesting a ceiling effect
for cell therapy. If results of this clinical trial are replicated in a larger randomized control trial,
transendocardial transplantation of CD34+ cells could be considered as an alternative
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therapeutic option to improve functional capacity as well as short-term event-free survival in
patients with NIDCM.

Study Critique
Strengths of this study include the specific inclusion and exclusion criteria, with one of
the inclusion criteria being NYHA class III symptoms. This is a strength because all individuals
had comparable symptoms which ensured adequate and fair comparisons. These criteria also
helped to create well-matched patient groups. In addition, included patients were followed in the
researchers’ heart failure outpatient clinic for at least 3 months, which allowed for adequate
optimization of medical therapy.
This study is hampered by the heterogeneity within the definition of DCM. Multiple tests
were performed on each patient prior to inclusion, but no biopsies were done to exclude
secondary cardiomyopathies. There was also no placebo arm which limits the evaluation of the
cell therapy effects. This study was also performed only at one center, with a small sample size,
and outside of the United States, which potentially limits the ability to extrapolate data to larger
or geographically different populations. The echocardiography data was analyzed by one
echocardiographer, which could be interpreted as a strength or a weakness. Although it
provides a sort of uniformity, multiple interpreters at multiple centers could provide valuable
information if there was interobserver agreement.

Level of Evidence: 1B

Study #3
Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for
Nonischemic Dilated Cardiomyopathy. Hare et al. 12

Study Objective
To evaluate the safety and efficacy of autologous versus allogeneic bone marrowderived human mesenchymal stem cells (hMSCs) in Nonischemic Dilated Cardiomyopathy
(NIDCM).
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Study Design
This was a randomized control trial in which 37 patients were recruited from the
University of Miami Hospital between December 2011 and July 2015 and randomized 1:1 to
receive either allo- or auto-hMSCs by transendocardial stem cell injection (TESI) in 10 left
ventricular sites. End points
evaluated

included

LVEF

and 6MWT, among others.
Table 4 outlines inclusion
criteria for this study.
Mean age of study
participants was 55.8 years.
29% of participants were
female, 35% were Hispanic,
and

50%

had

NYHA

functional class II symptoms. Average baseline test results for LVEF and 6MWT were 26.5% ±
9.64% and 422m ± 86.8m respectively.
Of the 37 patients who were randomized into one of the two groups of this study, 3 did
not receive the study injection of auto or allo-hMSCs: 1 withdrew consent before treatment, 1
had an ICD placed prior to injection,
and 1 died before treatment. The
study timeline and flow of patients
through the trial can be seen in
Figure 6. 12
All allo- and auto-hMSCs were
manufactured at the University of
Miami

Interdisciplinary

Stem

Cell

Institute. Auto-hMSCs were obtained
from participants 4-6 weeks prior to
cardiac

catheterizations

to

allow

ample time for sufficient ex vivo
expansion prior to transendocardial
injection of participant’s own cells.13
Allo-hMSCs were manufactured at
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the University of Miami Cell Production Facility from a pooled collection of donors. All allohMSCs donors were male, Caucasian, with a mean age of 25.4 years. Allo-hMSCs were from
11 men with a mean age of 58 years, and 6 women with a mean age of 55 years. Injections
were then administered transendocardially during cardiac catheterization using the Biosense
Webster MyoStar NOGA Catheter system.13 Injection sites for therapeutic administration were
selected to distribute sites evenly throughout the accessible left ventricular myocardium and to
prioritize safety of the transendocardial stem cell injection.
Prior to treatment administration, baseline assessment of all patients was performed
including chemistry and hematology laboratory tests, echocardiography, and CT scans or MRI
imaging of the chest, abdomen, and pelvis. Following cardiac catheterization and TESI, patients
were admitted to the hospital for a minimum of 2 days and were required to follow-up posttreatment at 2 weeks and at 2, 3, 6, and 12 months for safety and efficacy evaluation. LVEF was
evaluated at baseline and at 12 months. 6MWT results were evaluated at baseline, 6 months,
and 12 months.
The data analysis of this open-label study masked all parties involved in statistical
analysis of results. All patients who received study injection were included in analysis. “All
statistical tests were performed at alpha = 0.05 using 2-sided tests.” 12

Study Results
At 12 months post-treatment, the LVEF increased in the allo-hMSC group by 8.0% (CI:
2.8% to 13.2%, p = 0.004) compared to baseline which was found to be statistically significant,
but the LVEF increase of 5.4% in the auto-hMSC group was not statistically significant (CI: 1.4% to 12.1%; p = 0.116). The statistically significant increase in the allo-hMSC group resulted
in the post-treatment LVEF exceeding 40% in 46.7% of the patients in this group. The autohMSC group post-treatment LVEF exceeded 40% in only 22.2% of patients in this group.
At 12 months post-treatment, the 6MWT distance significantly increased in the allohMSC treatment group by 37.0 meters (CI: 2.0m to 72.0m, p = 0.04) compared to baseline. At
the same time point, the auto-hMSC treatment group 6MWT increase of 7.3 meters compared
to baseline was not statistically significant (CI: -47.8m to 33.3m, p = 0.71). Figure 7 shows
results of these end points. 12
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The primary safety endpoint measured in this study was the incidence of any treatmentemergent

serious

adverse

events

(TE-SAEs)

occurring within 30 days after treatment. There were
no TE-SAEs observed in the first 30 days. Two
deaths occurred post-injection in the auto-hMSC
group, but both events were considered to be
unrelated to the study treatment.
In summary, these results support clinical
efficacy of transendocardial stem cell infusion of
allo-hMSCs in the setting of nonischemic dilated
cardiomyopathy

since

a

statistically

significant

improvement from baseline was seen in the allohMSC group in LVEF and 6MWT, indicating that a
significant improvement of functional capacity in
these patients with NIDCM was achieved as a result
of this experimental therapy. If results of this clinical
trial are replicated in a larger randomized control
trial, TESI of allo-hMSCs could be considered as a
therapeutic option to improve functional capacity in
patients with NIDCM.

Study Critique
Strengths of this study include the stringent inclusion and exclusion criteria used to
select study participants, including all patients who received either treatment in the final data
analysis, and consistency with location of stem cell collection and culture. This study is
hampered by a very small sample size at a single hospital center, lack of a placebo group (by
trial design), and loss of patients due to withdrawal of consent or loss to follow-up. The trial
sample size was determined prospectively based on predicted rates of serious adverse events,
and, although the sample size is too small to draw concrete conclusions regarding efficacy of
therapy, the findings are valuable in designing future studies.
It is important to note that the mean age of the stem cell donors in the allo-hMSC group
was roughly one half of the mean age of the stem cell donors in the auto-hMSC group. This
significant mean age difference between the stem cells used in the two treatment groups in this
study could potentially account for the increased efficacy of the allo-hMSC treatment.
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Implications of this difference between treatment groups include the possibility that study end
points in both treatment groups would show statistically significant improvement compared to
baseline if the average age of stem cell donors for the auto-hMSC group was reduced to match
that of the allo-hMSC group, or that the study cannot be considered reliable due potential
confounding variables resulting from this difference.

Level of Evidence: 1B

DISCUSSION
Nonischemic dilated cardiomyopathy is a progressive and deadly disorder with a
significant global impact and only one curative treatment option at this time: a total heart
transplant. Stem cell therapy in the setting of NIDCM is hypothesized to provide another
curative option for this disorder as evidence shows potential for this therapy to regenerate
damaged heart tissue, in turn increasing functional capacity and, therefore, quality of life.
End point measurements of cardiac improvement after stem cell therapy being evaluated
in this paper include the 6-minute walk test (6MWT) and left ventricular ejection fraction (LVEF).
The 6MWT is frequently used to determine functional capacity in patients with heart failure. In
this test, the patient is asked to walk, self-paced, back and forth between 2 marked points on a
flat surface for 6 minutes. Rests are allowed and the total number of meters walked at the 6minute mark is calculated. A review paper has shown that the 6MWT is a reliable and valid test
for estimating functional capacity in patients with heart failure, as the test was between 83% and
91% accurate in predicting peak oxygen uptake (VO2) when total distance walked was less than
490 meters, with VO2 being universally accepted as a measurement for functional capacity.14
LVEF is defined as the percent volume that is ejected during systole from the left ventricle.
LVEF has been the primary parameter used in the diagnosis, management, and both symptom
severity and outcome predictor in patients with heart failure.15 This review focuses on recent
evidence that stem cell therapy causes short term improvement in the 6MWT and LVEF in the
setting of nonischemic dilated cardiomyopathy.
Overview of details and results of the three studies evaluated in this paper are
summarized in Table 5. Sample sizes of all three studies are too small to draw definitive
conclusions from results and the small sample sizes combined with the stringent inclusion and
exclusion criteria lead to restricted demographics in the studies. All three studies show
significant short-term improvement in 6MWT results and two of the three studies show
significant short-term improvement in LVEF after treatment with stem cell therapy, supporting
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the theory that stem cell therapy may stimulate regeneration of healthy heart tissue. This
suggests that larger scale future studies should be done to validate the results from these three
trials.
While all three studies include patients with nonischemic dilated cardiomyopathy and
evaluate safety and efficacy endpoints including LVEF and 6MWT, the specific type of stem cell,
delivery method, and follow-up time points vary greatly between the three studies. Butler et al.
was unique in that it is the first published experiment with intravenously-administered stem cells
in patients with any type of chronic cardiomyopathy. Vrtovec et al. is the first clinical study
investigating the effects of repetitive transplantation of CD34+ cells in patients with NIDCM,
although repetitive treatment administration was not associated with improved clinical response
except for a noticeable increase of myocardial viability in certain subsets of patients. Hare et al.
is the first study comparing allogeneic and autologous human mesenchymal stem cells in the
treatment of NIDCM.
Results regarding safety and efficacy of treatment in all three studies, in spite of
differences in stem cell type and delivery method, showed no life-threatening adverse effects or
concerns for patient safety. We assume that there were minor adverse side effects (i.e. pain
from bone marrow harvesting for auto-stem cell donors), but these studies only focused on
serious, short-term, and life-threatening adverse outcomes. This focus is appropriate for early
phase human trials, but future studies will be needed to further evaluate life-threatening adverse
events as well as other safety endpoints. Of note, it will be difficult to interpret data regarding
any adverse effects that arise after a significant amount of time has passed post-stem cell
treatment of NIDCM, since the morbidity and mortality of NIDCM is so high without treatment.
An important aspect of this experimental therapy to consider is the cost of treatment.
The current accepted bridging therapy to heart transplantation for NIDCM is the use of left
ventricular assist devices (LVAD), which cost several hundred thousand dollars to place and,
more often than not, require the patient to remain hospitalized while the LVAD is in place. Many
insurances do cover at least a significant portion of the cost of the LVAD when it is needed and
Medicare is currently in the progress of including LVAD costs in their coverage; however, the
device itself and the hospitalization it requires results in significant medical costs to both the
patient and insurance companies. Stem cell therapy for NIDCM is still in experimental stages
and the total cost of therapy is not known at this time, but it is estimated to be extremely
expensive due to the complexity and novelty of the procedures required to obtain, expand, and
administer the stem cells colonies. The LVAD has been proven to be an effective bridging
option for NIDCM patients awaiting heart transplantation, whereas stem cell therapies only
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appear to increase quality of life during brief short-term periods after treatment. Additionally,
repeat stem cell treatments only seem to improve longer term outcomes for a very small subset
of patients. At this time, it will be necessary to find a way to prolong the effects of stem cell
therapy in the setting of NIDCM in order for it to be considered an effective bridging therapy
option for heart transplant candidates. Stem cell therapy could, however, be effective in patients
with advanced NIDCM who are not candidates for heart transplantation. This treatment could
help improve their quality of life, and, hopefully, as this technology improves and advances, the
stem cell therapy could regenerate healthy myocardium, potentially reversing the effects of the
disease and further improving quality of life, as well as prolonging life.
The only potential bias noted in any study evaluated in this paper was involvement of
several authors from Study #1 (Butler et al.) with CardioCell, which is a global biotechnology
company that explores therapeutic applications of unique patented ischemia-tolerant
mesenchymal stem cells (itMSCs) manufactured under cGMP conditions. CardioCell has an
exclusive worldwide license from Stemedica Cell Technologies Inc. for the exploration of
therapeutic cardiovascular indications, including acute myocardial Infarction (AMI), chronic heart
failure (CHF), and peripheral artery disease (PAD).

Table 5: Overview of Studies
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CONCLUSION
Stem cell therapy is shown to be safe, well-tolerated, and effective in improving
functional capacity, quality of life, and short-term event survival in patients with nonischemic
cardiomyopathy. All three studies displayed short-term improvements in LVEF and/or 6MWT,
with a small sample size. No major adverse events were attributed to the interventions. Further
randomized controlled trials are warranted in order to validate long-term results in a larger
population before a clinical recommendation can be given; however, because of these positive
results and potential therapeutic effect, large institutions will likely be willing to fund future
studies. Further research should be done to explore the hypothesis that the positive findings are
a result of immunomodulatory factors stimulated by the act of transplantation, rather than the
stem cells, exclusively. If this is the case, a more cost-effective synthetic injection could likely be
created to stimulate the same response, limiting the need to harvest human stem cells. In
conclusion, stem cell therapy is a promising alternative therapeutic option for patients with
nonischemic cardiomyopathy.
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